Thermo Fisher ScientificBSP:TMOS34 +3.19%74 Current Ratio is 1.53 as of Mar. 2026, which is 8% below its 10-year median of 1.66. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$63.36 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks worse than 62.79% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Thermo Fisher Scientific's current ratio for the quarter that ended in Mar. 2026 was 1.53.
Thermo Fisher Scientific has a current ratio of 1.53. It generally indicates good short-term financial strength.
The historical rank and industry rank for Thermo Fisher Scientific's Current Ratio or its related term are showing as below:
BSP:TMOS34'
s Current Ratio Range Over the Past 10 Years
Min: 1.15 Med: 1.66 Max: 3.19
Current: 1.53
During the past 13 years, Thermo Fisher Scientific's highest Current Ratio was 3.19. The lowest was 1.15. And the median was 1.66.
BSP:TMOS34's Current Ratio is ranked worse than 62.79% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs BSP:TMOS34: 1.53
Thermo Fisher Scientific (BSP:TMOS34) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thermo Fisher Scientific Current Ratio Related Terms
Thermo Fisher Scientific Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:TMOS34 vs DHR, IDXX, A: Current Ratio Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Current Ratio distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a Current Ratio of 1.53 as of Mar. 2026. This is near median its historical median of 1.66. Over the past decade, Thermo Fisher Scientific's Current Ratio has ranged from 1.15 to 3.19. According to the industry distribution chart, Thermo Fisher Scientific ranks #135 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 62.8%.
Is Thermo Fisher Scientific's Current Ratio too high?
Thermo Fisher Scientific's current Current Ratio of 1.53 is near median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 3.19. The Medical Diagnostics & Research industry median Current Ratio is 1.96. Thermo Fisher Scientific's value of 1.53 is 21.9% below this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #135 out of 215 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Current Ratio compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #135 out of 215 companies for Current Ratio. This places Thermo Fisher Scientific in the lower half of its industry. The industry median Current Ratio is 1.96. Thermo Fisher Scientific's value of 1.53 is 21.9% below this benchmark. Historically, Thermo Fisher Scientific's own Current Ratio has ranged from 1.15 to 3.19 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 1.96, Thermo Fisher Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.96, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Current Ratio of 1.53 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Current Ratio is 1.53, which is near median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$63.36, compared to a current price of R$54.95 — trading 13.3% below its estimated fair value. The current Current Ratio is 1.53, which is near median its 10-year median of 1.66 and 21.9% below the Medical Diagnostics & Research industry median of 1.96. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Current Ratio is 1.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$54.95 is trading 13.3% below its estimated GF Value™ of R$63.36.
GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.
Key valuation signals for BSP:TMOS34:
Current Ratio: 1.53 (near median its 10-year median of 1.66)
GF Value™: R$63.36 vs. price of R$54.95 (13.3% below fair value)
Industry Position: 21.9% below the Medical Diagnostics & Research median (#135 of 215)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
